Activatable Nanoreporters for Macrophage Phenotype Tracking

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current diagnostic techniques for inflammatory diseases and cancer lack sensitivity and specificity for early detection, particularly in identifying macrophage phenotypes associated with disease progression, such as the M2 phenotype in solid tumors like triple-negative breast cancer.

Innovation Solution

Development of activatable lipid nanoparticle systems, specifically M1 and M2 nanoreporters, that selectively emit a fluorescent signal in the presence of nitric oxide and Arginase 1, respectively, allowing for non-invasive, real-time monitoring of macrophage phenotypes in various disease models.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional diagnostic techniques are used for inflammatory diseases and cancer, then diagnosis can be performed, but sensitivity and specificity for early detection are insufficient

Engineering Contradiction:

Improvedetection sensitivityVSAvoiddiagnosis accuracy

Core Design Contradiction:

Measurement precisionVSReliability

Solution Approach 1:

The patent changes the detection parameter from general biomarker detection to specific macrophage phenotype detection through fluorescent nanoprobes. The nanoprobes are designed to detect specific enzymes (arginase-1 for M2 macrophages, iNOS for M1 macrophages) with high sensitivity, enabling early detection before clinical symptoms appear. This parameter change from non-specific to specific detection resolves the contradiction between sensitivity and diagnostic reliability.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent replaces conventional mechanical/biochemical diagnostic methods with optical detection using fluorescent nanoprobes. The nanoprobes emit fluorescent signals when detecting target enzymes, allowing non-invasive, real-time monitoring with high sensitivity. This substitution of detection mechanism enables early detection while maintaining diagnostic accuracy, resolving the technical contradiction.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Productivity

If conventional biomarker detection methods are used, then disease presence can be identified, but real-time monitoring of macrophage phenotypes is not possible

Engineering Contradiction:

Improvemonitoring capabilityVSAvoiddetection timing

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent implements continuous monitoring capability through fluorescent nanoprobes that can track macrophage phenotype changes in real-time. The nanoprobes remain active in the tumor microenvironment, continuously detecting enzyme activity and providing ongoing information about disease progression and treatment response. This continuous action enables real-time monitoring without interruption, resolving the contradiction between monitoring capability and detection timing.

Inventive Principle:

Principle #20Continuity of useful action

Solution Approach 2:

The nanoprobes are designed to self-assemble and automatically detect target enzymes without requiring external intervention. Once administered, they autonomously navigate to the tumor microenvironment, bind to target enzymes, and emit fluorescent signals. This self-service capability enables real-time monitoring while eliminating the need for repeated sampling or complex procedures, resolving the time loss contradiction.

Inventive Principle:

Principle #25Self-service

3Measurement precision

If invasive biopsy methods are used for diagnosis, then accurate tissue samples can be obtained, but patient comfort and treatment accessibility are reduced

Engineering Contradiction:

Improvedetection accuracyVSAvoiddiagnostic accessibility

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The patent replaces invasive mechanical biopsy procedures with non-invasive optical imaging using fluorescent nanoprobes. The nanoprobes are administered systemically and accumulate in the tumor microenvironment, where they detect target enzymes and emit fluorescent signals that can be imaged externally. This substitution eliminates the need for invasive tissue sampling while maintaining high detection accuracy, resolving the contradiction between accuracy and accessibility.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The nanoprobes serve as intermediaries between the diagnostic system and the tumor microenvironment. Instead of directly accessing tissue through biopsy, the nanoprobes mediate the detection process by navigating to the tumor, binding to target enzymes, and transmitting information through fluorescent signals. This intermediary approach maintains detection accuracy while eliminating invasive procedures, resolving the technical contradiction.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables early diagnosis and longitudinal monitoring of tumor progression and inflammatory responses, providing predictive insights into disease outcomes and treatment efficacy.

Implementation Method 1

successfully synthesized and characterized Arginase 1 sensing lipid nanoparticles that can selectively emit a strong fluorescent signal in the presence of M2 macrophages

Methodology Applied

Scientific EffectFluorescence: Fluorescence